Co-Founder
NanoCube Health
NanoCube Health is developing Duobots™, a nanorobotics platform that utilizes artificial intelligence to enable early detection of pancreatic cancer, real-time treatment monitoring, and targeted drug delivery to cancer cells. This technology addresses the critical challenge of late-stage diagnosis in pancreatic cancer, which has a low survival rate due to the absence of effective early screening methods.
- Artificial Intelligence
- Biotechnology
- Healthcare Technology
Updated 7 months ago
Funding
Funding rounds are not available yet.
Founders
Product
Problem
Pancreatic cancer is often diagnosed late due to a lack of early symptoms and effective screening methods, resulting in low survival rates. Currently, 7 out of 10 individuals diagnosed with pancreatic cancer have a survival period of less than 12 months. The absence of early detection tools contributes significantly to these poor outcomes.
Solution
NanoCube Health is developing Duobots™, a nanorobotics platform leveraging artificial intelligence for early pancreatic cancer detection, real-time treatment monitoring, and targeted drug delivery. The Duobots™ technology aims to identify pancreatic cancer at its earliest stages, monitor the effectiveness of treatments in real-time, and deliver drugs directly to cancer cells, improving patient outcomes. This comprehensive approach addresses the critical need for earlier diagnosis and more effective treatment strategies for pancreatic cancer.
Target Audience
The primary target audience includes individuals at high risk for pancreatic cancer, oncologists, and medical researchers focused on early cancer detection and treatment.
Features
- AI-driven nanorobotics platform for early detection of pancreatic cancer
- Real-time monitoring of treatment progress using nanorobotics
- Targeted drug delivery to cancer cells via nanorobots